Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2020

View Archived Issues

AI finds structurally unique antibiotics

New dihydroquinoxalinone analogues targeting tubulin with promising preclinical antitumor action

New receptor tyrosine kinase inhibitor acts as a broad-spectrum coronavirus inhibitor in vitro

Neuronal necrosis induced by YAP deprivation mostly occurs in early stages of Alzheimer's disease

FDA approves Nexlizet tablet as first non-statin LDL-C lowering combination medicine

Positive top-line results for phase III ALLIUM study of Exblifep for cUTI

Novel alphaVbetea6-targeted PDC shows promise in preclinical models of PDAC

Progranulin as a novel prognostic biomarker in community-acquired pneumonia

Phase I data for novel lentiviral vector therapy for children with Fanconi anemia

First patient enrolled in first-in-human study of NI-006

Dosing begins in phase I study of KAN-101 for the treatment of celiac disease

CD5.CAR/28zeta CAR T cells show antitumor activity in relapsed/refractory T-cell lymphoma

FDA approves IND and grants orphan drug status for HBM-9167

Boehringer Ingelheim Pharma patents KLKB1 inhibitors

Microglial fresh start helps heal brain trauma

Inflazome divulges new NLRP3 inflammasome inhibitors

Leo Pharma A/S presents RORC ligands

Amgen and Carmot Therapeutics identify USP30 inhibitors

Epizyme discloses new SETD2 inhibitors

DNA-PKcs inhibitor increases the antitumor activity of localized DNA-damaging therapies

S1PR1 is required for tumor vascular normalization, enhancing the efficiency of antitumor agents

Clene announces interim blinded data from phase II study of CNM-Au8 for vision impairment in MS

Spark Therapeutics opens enrollment in phase I/II study of SPK-3006 in late-onset Pompe disease

FDA approves Nurtec ODT for acute treatment of migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.